Startups Target Lab Automation Gaps with AI and Modularity
The lab robotics sector is seeing startups address key automation challenges across three areas: protocol translation layers, modular physical hardware, and AI-driven robotic intelligence. Ginkgo Bioworks plans an early 2026 launch of Autonomous Labs, using GPT-5-powered robotics for remote cell-free protein synthesis experiments. This trend reflects a broader push to make wet lab automation more efficient and accessible for complex workflows like viral vector development.
- Manual processes in cell and gene therapy manufacturing can contribute to 60% of costs and increase the risk of batch failure due to the complexity and variability of working with patient-derived materials. Automation, including the use of electronic batch records (EBRs) within a LIMS, is critical for enforcing SOPs, reducing manual data entry errors, and ensuring data integrity for GMP compliance. - The global cell and gene therapy CDMO market was valued at approximately $6.31 billion in 2024 and is projected to grow to around $74.03 billion by 2034, reflecting a compound annual growth rate of about 27.92%. This growth is driven by the need for specialized manufacturing facilities and expertise, though the sector has seen an imbalance with manufacturing capacity growth outpacing the number of active clinical trials since 2019. - AI and machine learning are being integrated into bioprocessing to move from simple real-time monitoring of parameters like pH and dissolved oxygen to predictive analytics for process control and optimization. Companies like 908 Devices are enabling more frequent, automated measurements of glucose and lactate, providing richer datasets for AI-driven process improvements. - Ginkgo Bioworks is expanding its automation services beyond in-house use, offering modular, reconfigurable automation carts (RACs) and orchestration software to partners like Aura Genetics to scale diagnostic testing workflows. This "horizontal platform" approach aims to provide broad access to automated cell programming and high-throughput screening. - The biotech funding landscape has shifted, with investors now demanding more significant clinical validation before committing capital, favoring companies with strong Phase 1b or Phase 2a data. While early-stage funding is more competitive, nearly $15 billion was invested in cell and gene therapy programs in 2025. - Key challenges in scaling up viral vector production include low and inconsistent yields, purification bottlenecks that risk vector degradation, and ensuring regulatory compliance for safety, purity, and potency. These manufacturing complexities are a primary driver of high therapeutic costs and limit broader patient access. - Startups in the modular robotics space, such as Germany-based RobCo, are developing reconfigurable robotic arms with low-code software to make automation more affordable and flexible for smaller to mid-sized labs and manufacturers. This trend addresses the high upfront investment and technical expertise typically required for automation systems. - A significant hurdle in cell and gene therapy data management is the lack of standardized assays and data formats, which complicates the implementation of Quality by Design (QbD) principles needed to manage process variability and ensure product consistency. AI is seen as a key tool to analyze disparate data points and identify critical process parameters.
